Applied Biological Materials (abm)

Superficial Spreading Melanoma Cell Line (MM052)

Product Code:
 
ABM-T8085
Product Group:
 
Cell Lines
Host Type:
 
Human
Regulatory Status:
 
RUO
 

No additional charges, what you see is what you pay! *

CodeSizePrice
ABM-T80851x10^6 cells / 1.0 mlEnquire
An MTA must be signed before products can be dispatched. Please contact us for more information.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Canada.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Description:
This melanoma cell line panel is unique from all other available melanoma cell lines as these cells have been raised under conditions that prevent phenotype switching.. Derived from a skin metastasis with superficial spreading melanoma (SSM), MM052 displays low sensitivity to MEKi. This cell line is suitable for high-throughput screening/drug testing and 3D cell culture and can produce xenograft tumors when injected into immunocompromised mice. Additional cell lines from this panel include:Cat. T8080 - Acral Lentiginous Melanoma Cell Line (HBL (MM001))Cat. T8081 - Acral Lentiginous Melanoma Cell Line (MM011/LND1)Cat. T8082 - Lymph Node Metastasis SS Melanoma Cell Line (MM029)Cat. T8083 - Bladder Metastasis Nodular Melanoma Cell Line (MM031)Cat. T8084 - Lymph Node Metastasis Melanoma Cell Line (MM034)Cat. T8085 - Superficial Spreading Melanoma Cell Line (MM052)Cat. T8086 - Lymph Node Metastasis Melanoma Cell Line (MM057)Cat. T8087 - Lymph Node Metastasis SS Melanoma Cell Line (MM074)Cat. T8088 - Lymph Node Metastasis SS Melanoma Cell Line (MM165)
Donor History:
Derived from a skin metastasis with superficial spreading melanoma (SSM)
Growth Conditions:
PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Ham's F10 Medium + 10% FBS + 2 mM L-Glutamine (G275) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO2.
Growth Properties:
Adherent
Markers:
WT(BRAF, C-KIT, PTEN,P53,MET), NRAS (Q16R)
Population Doubling:
48-72
Split Ratio:
1:2 to 1:3
Tissue:
Skin

References

Sabbah,   M.; Krayem, M.; Najem, A.; Sales, F.; Miller, W.; Del Rincon, S.; Awada, A.;  Ghanem, G.E.; Journe, F. Dasatinib Stimulates Its Own Mechanism of Resistance   by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified   c-Kit. Mol Cancer Res 2021, 19, 1221?1233, doi:10.1158/1541-7786.MCR-20-1040   Najem, A.; Krayem, M.; Sal?s, F.; Hussein, N.; Badran, B.;   Robert, C.; Awada, A.; Journe, F.; Ghanem, G.E. P53 and MITF/Bcl-2 Identified   as Key Pathways in the Acquired Resistance of NRAS-Mutant Melanoma to MEK   Inhibition. European Journal of Cancer 2017, 83, 154?165,   doi:10.1016/j.ejca.2017.06.033.    Rambow, F.; Rogiers, A.; Marin-Bejar, O.; Aibar, S.; Femel, J.;   Dewaele, M.; Karras, P.; Brown, D.; Chang, Y.H.; Debiec-Rychter, M.; et al.   Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell 2018, 174,   843-855.e19, doi:10.1016/j.cell.2018.06.025.